



PRESS RELEASE

REVENUE FOR THE FIRST HALF OF 2009

Very buoyant growth: +111%

Further intensification of activity in the United States

Marseille, 31 August 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces revenue of €3.3 million for its first half to 30 June 2009.

<i>(in thousands of euros)*</i>	30 June 2009	30 June 2008	Δ	Δ at constant forex
Products	3,155	1,415	+118%	106%
Services	116	137	+8%	8%
Consolidated total	3,271	1,552	+111%	99%

*IFRS standards

Revenue for the first half of 2009 was up 111% compared to the same period of 2008 (€1.6 million). At constant forex, revenue growth was +99%.

With revenue from Products up +118% at €3.1 million, over the first six months of 2009 IPSOGEN has thus already recorded 80% of the figure recorded over the previous fiscal year.

All of the Group’s tests contributed to this growth in activity; this was notably the case of JAK2 tests, showing another record growth of +270% between the first half of 2008 and the first half of 2009, to be compared to the growth of +169% between 2007 and 2008.

Revenue from Services, an activity that the Company is continuing to divest, rose by +8% to €0.1 million and now accounts for 3.5% of total activity, versus 7% a year ago.

Geographically, IPSOGEN is continuing to pursue its overseas development. The US market recorded buoyant growth compared to the same period of 2008 (493%), and represented 50% of the Group’s diagnosis activity in the period.

Vincent Fert, President and CEO, states: *“The buoyant growth of our sales is the result of our strategic choice to master and develop a direct commercial presence in Europe and the United States. Over the last half, the launch of a number of products in leukemia and the recognition of the value of the genomic grade in one of the major breast cancer guidelines lay witness to the dynamism and quality of our teams who pave the way for our future growth. The figures published today validate our positioning on the rapidly-growing molecular diagnosis of cancer and personalized medicine market.”*

About IPSOGEN

IPSOGEN, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

With more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly-skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

Ipsogen employed 60 people as of June 30, 2009. Its headquarters are located in Marseille, France. The company has also a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: www.ipsogen.com



Contacts

IPSOGEN

Vincent Fert

President and CEO
Tel: +33 (0)4 9129 3090
fert@ipsogen.com

Stanislas Piot

CFO
Tel: +33 (0)4 9129 3090
piot@ipsogen.com

NewCap

Financial Communication and Investor Relations

Axelle Vuillermet & Pierre Laurent
Tel: +33 (0)1 44 71 94 93
ipsogen@newcap.fr